NuPathe

Teva Completes $144 Million NuPathe Deal Read more here

Teva buys NuPathe to Expand Central Nervous System Business Read more here

NuPathe Wins U.S. FDA Approval for Migraine Skin Patch Read more here

FDA is Readying to Rule on NuPathe’s Revised Application for its Patch to Treat Migraines Read more here

FDA Accepts NuPathe Inc. (PATH)'s Migraine Patch NDA Resubmission for Filing Read more here

NuPathe Inc. CEO to Present at the Leerink Swann Emerging Technologies in Pain Medicine Conference Read more here

NuPathe Licenses Novel Drug Delivery Technology from University of Pennsylvania Read more here